Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease that can lead to cirrhosis and its complications. The lack of strict diagnostic criteria for AIH complicates diagnosis and delays the initiation of appropriate therapy. Treatment selection and patient management remain challenges.
OBJECTIVE
To highlight the diagnostic and therapeutic aspects of AIH based on a clinical case.
CLINICAL CASE
A 33-year-old female presented with significant cytolysis and cholestasis. A differential diagnosis ruled out viral hepatitis, liver storage diseases, and drug-induced liver injury (the patient had taken paracetamol and amoxicillin-clavulanate for a recent viral infection). Anti-SLA/LP antibodies were detected, while ANA, AMA, ANCA, SMA, and anti-LKM were within reference ranges. A liver biopsy revealed features of AIH and grade 1 steatosis. The final diagnosis was chronic AIH with high cytolytic activity, intrahepatic cholestasis, and parenchymal jaundice. Immunosuppressive therapy with prednisolone (40 mg/day) and azathioprine (50 mg/day) was initiated, with dosage adjustments for side effects. Despite four years of therapy, full biochemical and morphological remission was not achieved, and the risk of cirrhosis remains. This case underscores the challenges of diagnosing AIH and its potential overlap with cholestatic liver diseases. The article also discusses the need to monitor therapy-related side effects and the role of thiopurine S-methyltransferase testing in treatment.
CONCLUSION
The heterogeneity of AIH symptoms complicates early diagnosis. A comprehensive approach, including autoantibody testing and imaging, is essential for timely and accurate diagnosis.